Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-30 20:18:18 - browse：47

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： In 'major milestone,' FDA approves first cell therapy for solid tumors

hotspot

WSS

Weight loss drugs aren’t covered by Obamacare. That may change

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

New CMS data security rules will hurt Medicare, Medicaid research

Why Novartis is going to walk from its acquisition of MorphoSys

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Why Novartis is going to walk from its acquisition of MorphoSys

Wikipedia

Wikipedia

focus

Medical leaders decry Supreme Court decision on affirmative action

Problems with a popular proposal to regulate AI in health care

Walensky prepares to leave CDC — and Congress — behind

MD Anderson's Padmanee Sharma responds to research credit suit

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Apple is now the first public company to be valued at $3 trillion

340B reform proposal comes out of Senate working group

Affirmative action in medical school literally saved lives

Weight loss drugs aren’t covered by Obamacare. That may change

hotspot

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Bernie brings in new pharma CEOs to talk drug prices

MD Anderson's Padmanee Sharma responds to research credit suit

A new drug could help frostbite victims avoid its ravages

Surprise medical billing ban raises prices elsewhere

Hospitals are piloting generative AI tools as regulators play catch

knowledge

focus

hotspot

focus